Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial.

The study saw 114 healthy adults inoculated with the virus and then given the antiviral, dubbed S-337395, or placebo for five days. Individuals treated with S-337395 showed a “statistically significant reduction in viral load compared to the placebo group,” hitting the study’s primary endpoint.